WHO ICTRP trial
Role of Thalidomide in prevention of stroke due to basal exudates in Tuberculous…
CTRI/2025/01/078846 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2025/01/078846 |
|---|---|
| Public title | Role of Thalidomide in prevention of stroke due to basal exudates in Tuberculous Meningitis |
| Scientific title | Thalidomide as treatment of basal exudates in Tuberculous Meningitis: A prospective randomized open blinded endpoint (PROBE) study. - NIL |
| Primary sponsor | Rajesh Kumar Singh |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | India |
| Conditions | Health Condition 1: A170- Tuberculous meningitis |
| Interventions | Intervention1: Thalidomide: The patients will be given oral Thalidomide as per 2-4 mg/kg body weight and the target dose will be based on the tolerability of the patient. The treatment will be given for a period of two months. This… |
| Registration date | Jan 16, 2025 |
| Target size | 80 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: